source
- Sanofi halts Nurix STAT6 degrader program two months after phase-1 startSanofi announced it is ending its collaboration with Nurix on a STAT6 degrader, just two months after the drug entered a phase-1 study. The two companies have worked together since 2019, with Sano…
- MiniMed appoints diabetes and digital health veteran David Segal as chief medical officerMiniMed, the insulin pump maker that spun off from Medtronic, announced the appointment of Dr. David Segal as its new chief medical officer. Segal replaces Dr. Robert Vigersky, who has served as C…